Adding faster-acting insulin aspart to basal insulin significantly improved glycaemic control in adults with Type 2 diabetes : the onset 3 trial

Saravanan, P.; Rodbard, H.; Tripathy, D.; Velazquez, M. V.; Demissie, M.; Can Tamer, S.; Piletic, M.

Author

Saravanan, P.
Rodbard, H.
Tripathy, D.
Velazquez, M. V.
Demissie, M.
Can Tamer, S.
Piletic, M.

Affiliation

University of Warwick; George Eliot Hospital, Nuneaton; Endocrine and Metabolic Consultants, Rockville, Maryland, USA; University of Texas Health Science Center, USA; Audie L. Murphy VA Hospital, San Antonio, Texas, USA; Hospital General Regional 110, Guadalajara, Mexico; Novo Nordisk A/S, Søborg, Denmark; General Hospital, Novo Mesto, Slovenia

Publication date

2017-03-08

Subject

Diabetes

Metadata

Show full item record

Abstract

Poster abstract P111 in section 'Basic and clinical science posters: new insulins, technology, therapies and treatment' from the Diabetes UK Professional Conference 2017, Manchester Central, Manchester, 8–10 March 2017.

Citation

Saravanan P, Rodbard H, Tripathy D, Velazquez MV, Demissie M, Can Tamer S, Piletic M. Adding faster-acting insulin aspart to basal insulin significantly improved glycaemic control in adults with Type 2 diabetes: the onset 3 trial. Diabetic Medicine. 2017 Mar;34(S1):69. doi: 10.1111/dme.14_13304.

Type

Conference Output